Hyperactivation of the PI3K signaling is common in human cancers, including gliomas, but the precise role of the pathway in glioma biology remains to be determined. Some limited understanding of PI3K signaling in brain cancer come from studies on neural stem/progenitor cells (NSPCs) where signals transmitted via the PI3K pathway cooperate with other intracellular pathways and downstream transcription factors to regulate NSPC proliferation. To investigate the role for the PI3K pathway in glioma initiation and development, we generated a mouse model targeting the inducible expression of a Pik3ca H1047A oncogenic mutation and simultaneous deletion of the PI3K negative regulator, Pten, in NSPCs. We show that the expression of a Pik3ca H1047A was sufficient to initiate tumorigenesis but that simultaneous loss of Pten, was required for the development of invasive, high-grade glioma. Mutant NSPCs exhibited enhanced neurosphere forming capacity which correlated with increased Wnt signaling. We also show that loss of CREB in Pik3ca-PTEN tumors led to a longer symptom-free survival in mice. Taken together, our findings present a novel mouse model for high-grade glioma with which we demonstrate that the PI3K pathway is important for initiation of tumorigenesis and that disruption of downstream CREB signaling attenuates tumor expansion.
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INTRODUCTION
Although our understanding of the cellular and molecular mechanisms controlling brain cancer pathogenesis has progressed over the last decades, the therapies available have not translated to improved patient outcome. This is exemplified in the most common and deadly high-grade glioma (HGG) in adults, glioblastoma (GBM), where post-therapy survival for most patients ranges between 8-14 months. Since the pioneering work by Holland and colleagues 22 , genetically engineered mouse models have demonstrated that various gene combinations, overexpressing and/or targeting growth factors, growth factor receptors, oncogenic pathways and tumor suppressors in both brain progenitor or differentiated cells can initiate glioma development. These models, particularly those mimicking genetic alterations seen in patient tumors have proven to be invaluable in understanding the molecular events underlying the development of brain tumors, with the first models expressing constitutively activated mutant growth factor receptors (EGFR) or mutated key downstream signaling molecule (Ras, Akt) 21, 22 .
Numerous mouse models have since been generated using transgenic or gene modifying technologies targeting many genes 1, 58 . Genes enabling the initiation of high-grade gliomas include combinations of NF1, TP53, PTEN, AKT, Ras, INK4a/ARF 1, 2, 10, 43 . Many models have targeted glial cells, which are the cells enriched in human glioma 10, 13, 21 . Other mouse models show that gene mutations in oligodendrocyte precursor cells or fully differentiated astrocytes or neurons can initiate glioma development 16, 35 . The role of brain tumor stem cells (BTSCs) in fueling tumor growth has been demonstrated in a number of mouse models targeting genetic mutations/deletions in NSPCs 1, 2, 22, 26, 35, 43, 49 and highlighted by a study demonstrating that ablation of BTSCs inhibited tumor growth 59 . With the better understanding of single gene or gene combinations driving HGG development, recent translational research has turned to modelling HGG by manipulating specific factors of cell signaling networks which can been targeted by pathway-specific drugs.
The signaling pathways driving HGG pathobiology overlap with those activated in many cancers and involve complex interactions between oncogenes and tumor suppressors. Most oncogenes and tumor suppressors are regulatory factors of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. Both pathways activate a cascade of downstream kinases which lead to the activation of specific transcription factors, including the cAMP response element binding protein (CREB), which is upregulated in GBM and has a role in NSPC and GBM cell proliferation 12, 45 . Emerging evidence suggest that oncogenic PI3K and MAPK signals converge with Wnt signaling to regulate cancer cell growth and proliferation 44 and that in GBM, Wnt signaling has a role in cancer stem cell maintenance 48 .
When one considers the upstream components of the PI3K pathway including the epidermal growth factor receptor (EGFR) and the PI3K catalytic and regulatory subunits, PIK3CA and PIK3R1 as well as the pathway's main negative regulator, phosphatase and tensin homolog (PTEN), up to 63% of HGGs, including GBM, exhibit an alteration in at least one of these genes 31 . A recent study of cancer driver mutations shows that the catalytic subunit of PI3K, encoded by the PIK3CA gene, is amongst the three major oncogenic drivers in GBM; the other drivers are the EGFR and TP53 52 . Indeed, PIK3CA mutations are reported to be present in up to 17% of all pediatric and adult brain cancer types with primary higher grade and treatment resistant brain tumors exhibiting the highest mutation rates 31 . The full activation of the PI3K pathway not only requires enhanced catalytic activity to drive key downstream kinases such as Akt but also requires the inactivation of the lipid phosphatase activity of PTEN, which dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to the inactive PIP2 form 8, 14 . The precise role of PTEN in PI3K-driven HGG/GBM remains unclear, since recent discoveries demonstrate multiple PI3K-independent biochemical and cellular PTEN functions 6, 51 . Deletion of PTEN in neural stem and progenitor cells leads to enhanced proliferative activity in the stem cell niche but no tumor development 19, 20 . However, Pten deletion in combination with p53 and/or Rb1 loss results in the development of astrocyte-derived high-grade tumors 10 . An inducible viral expression system targeting NSPCs or glial cells, established the importance of platelet-derived growth factor-A (PGFA) in high-grade glioma initiation and the role of additional mutations of other genes, including Pten and NF1, in accelerating tumor development and determining the proneural GBM subtype 43 . The effects of pro-oncogenic mutations involving the PI3K catalytic (p110α) and regulatory (p85) subunits have not been investigated in mouse brain but combined activation of Ras and Akt in mouse neural progenitors resulted in glioblastoma formation 22 , although neither oncogene alone led to tumor development.
In an effort to understand the key events in brain tumor development involving the PI3K pathway, we targeted the PI3K pathway in mouse NSPCs by conditional activation of an oncogenic mutation in Pik3ca, the gene encoding the PI3K catalytic p110α catalytic subunit of PI3K 29 , in combination with the deletion of the PI3K pathway negative regulator, PTEN. To investigate the downstream transcriptional programs regulated by the PI3K pathway in our mouse model, we deleted CREB in Pik3ca-Pten mutant NSPCs and show that upon CREB loss tumor growth is attenuated via inhibition of mutant cell proliferation and subsequent conversion into a less aggressive tumor type.
RESULTS

Activation of Pik3ca H1047R expression in NSPCs is sufficient for tumor initiation but simultaneous deletion of Pten is necessary for the development of invasive tumors.
The Nestin-CreER T2 transgene used restricts Cre-recombinase expression to the sub-ventricular zone (SVZ) and the recombination only occurs following tamoxifen administration 25 . First, mice heterozygous for a latent Cre recombinase (Cre)-inducible knock-in of the Pik3ca H1047R mutation (Pik3ca H1047R-lox ) 29 and/or two Cre-inducible Pten deletion alleles (Pten loxP/loxP ) 20 were crossed with mice expressing a single (heterozygous) Nestin-CreER T2 transgene. Further F1 crosses generated mice which were heterozygous for mutant Pik3ca H1047R (Pik3ca H1047R-lox -Nestin-CreER T2 ) and homozygous Pten deletion (Pten loxP/loxP -Nestin-CreER T2 ) (Pten ∆ ).
Control Pik3ca H1047R-lox -Pten loxP/loxP mice without the Nestin-CreER T2 transgene but treated with tamoxifen, did not develop neurological symptoms, nor show evidence of tumor growth over the experimental time window of 200 days ( Fig. 1A ). Single mutant Pten  mice showed normal brain size with no overt abnormalities but did exhibit increased SVZ cellularity and proliferation compared to controls ( Fig. 1A) . Examination of single mutant heterozygous Pik3ca H1047R mouse brains between 50 to 150 days post-tamoxifen administration revealed the presence of tumors in the lateral ventricles ( Fig. 1A ).
Tamoxifen-treated double mutant Pik3ca H1047R-lox -Pten loxP/loxP -Nestin-CreER T2 (hereafter referred to as Pik3ca H1047R -Pten  ) 6-8-week-old mice, resulted in a completely penetrant (100%; 30 from 30 mice) neurological phenotype, apparent 55-90 days after tamoxifen administration. An early sign of ill health was a decline in body weight, compared to controls, in both male and female mice ( Fig. 1B) , followed by the appearance of progressively more severe neurological symptoms. The first neurological manifestation was ataxia, followed by sporadic seizures and a gradual increase in seizure frequency and length. Mice were culled when weight loss was more than 15% of the experiment start weight and/or when seizures occurred more than three times per day and at least one seizure lasted more than one minute. These criteria were deemed as the experimental endpoint. All tamoxifen-treated mice mutant mice reached the experimental endpoint between 55 and 90 days ( Fig. 1C ) and were subsequently culled. Furthermore, single mutant Pik3ca H1047R expression or Pten mice showed no body weight decrease, signs of brain dysfunction, nor reduced survival over 200 days (Fig 1B, C) . When Pik3ca H1047R -Pten  mutations were activated in one day old newborn mice (P1) via tamoxifen treatment of the mother and transmission of the tamoxifen to pups via the mother's milk, the pups began exhibiting severe neurological symptoms between 28 and 43 days (Fig. 1C ), earlier than in adult mice treated with tamoxifen. P1 tamoxifen-treated mouse brains showed the presence of tumors, consistent with those seen in adult mice.
Histological examination of brains demonstrated that compared to control mouse brains, Pik3ca H1047R -Pten  mouse brains showed hypercellularity of the SVZ, with multiple tumor nodules protruding into the lateral ventricles ( Fig. 1D , upper panel) and tumors completely filling the anterior lateral ventricles ( Fig. 1D , lower panels). Further examination showed the presence of multiple hypercellular clusters lining the SVZ and tumor cell migration into the developing tumor nodules ( Fig. 2A, B ). Away from the lateral ventricles, tumor cells invaded the brain parenchyma and white matter tracts, including the corpus callosum ( Fig. 2C ). Apoptotic cells were scattered within tumors (not shown), lying amongst atypical, irregularly arranged tumor cells and blood vessels ( Fig. 2D ).
Immunohistochemical analysis of Pik3ca H1047R -Pten  brains showed that tumors expressed glial fibrillary acidic protein (GFAP) and β-III-tubulin (Tuj1) ( Fig. 2E) showing that the NSPCs from which the tumors developed could differentiate into glial-like and neuronal-like cells. pAKT (S473) and pRps6 expression were highly expressed in all tumor cells ( Fig. 2F) , evidence that the PI3K pathway was activated by the mutations. Activation of additional oncogenic signaling and transcriptional pathways was observed by examining phospho-ERK1/2 (pERK1/2) and phospho-CREB (pCREB) expression ( Fig. 2F ). Proliferating cell nuclear antigen (PCNA), Ki67 and nestin expression demonstrated that tumors also harbored proliferating, immature cells (Supplemental Fig.S1 ).
Overall, the histopathological analysis of the mouse brain tumors demonstrated heterogeneous features overlapping with both lower (II) and higher (III) grade astrocytic tumors. Specifically, the presence of atypical cells, evidence of cells undergoing apoptosis and tumor cell invasion into white matter tracts is consistent with low grade / WHO grade II astrocytoma, while the presence of blood vessels within tumors, suggests the presence of tumor phenotypes consistent with high-grade astrocytoma / WHO grade III.
Mutant NSPCs exhibit enhanced proliferation and migration
Since mutant mice succumbed due to neurological complications associated with tumor growth, prior to broad dissemination of the disease, we assessed the invasive and functional characteristics of mutant cells in vitro. To obtain pure mutant NSPCs, SVZ tissue was used to isolate and propagate NSPCs from Pik3ca H1047R -Pten lox/lox -UBC-Cre ERT2 mice 30 and Cremediated recombination was induced, in vitro, by the addition of 4-OH-T to the medium for 24h. mutant neurosphere cells showed the presence of more filopodia, compared to controls (Fig. 3A,   B ), a feature associated with a more invasive, malignant phenotype in GBM and some cancer cell lines 41 . Incorporation of the thymidine analog, 5-ethynyl-2´-deoxyuridine (EdU) and flow cytometry analysis showed that Pik3ca H1047R -Pten  cells had a higher proliferation rate compared to parental Pik3ca-Pten wild-type cells ( Fig. 3C ). Mutant cells showed enhanced pAKT expression, in the presence or absence of EGF and bFGF ( Fig. 3D ). Correlating with enhanced proliferation, mutant cells exhibited increased expression of cyclins B1 and D1. Both control and mutant cells exhibited similar proportions of nestin-expressing cells (~97%) (Supplemental Fig.   S2 ).
Recombination in 4-OH-T treated cells was confirmed by PCR (data not shown) and loss of Pten
Seeding single neurospheres into a gel matrix showed that Pik3ca H1047R -Pten  NSPCs migrated to cover more than three times the area compared to control NSPCs at 48h ( Fig. 3E ,F), demonstrating that mutant cells have increased migratory capacity. Seeding cells at high density for 72h showed that mutant NSPCs detached and migrated away from spheres, unlike control NSPCs, which did not exhibit this behavior under the same seeding conditions (Supplemental Fig.S4 ).
Mutant NSPCs exhibit enhanced sphere-forming capacity, persistent nestin expression and
Wnt pathway activition
To determine the long-term proliferation differences between mutant and control NSPCs, cumulative growth was measured over 8 passages (8 weeks) . Pik3ca H1047R -Pten  cells showed significantly higher cell number from week two onward and almost four times more cells by eight weeks (Fig. 4A ). To elucidate the differences seen in cumulative growth, we next investigated the neurosphere-forming efficiency (a correlate of neural stem cell potential) differences between mutant and control NSPCs. Use of extreme-limiting dilution analysis (ELDA) 24 to measure neurosphere-forming efficiency, showed that in neurosphere culture conditions, the sphere-forming capacity of Pik3ca H1047R -Pten  cells (1 NSFU (neurosphere forming unit) / 1.55 cells seeded) was lower than control cells (1 NSFU / 2.01 cells seeded) ( Fig.   4B ). To test the inherent neurosphere forming stability of the NSPCs, we subjected the cells to alternating rounds of growth in neurosphere medium, serum-containing medium and a return to neurosphere medium to evaluate the ability of the cells in maintaining their neurosphere forming capacity under conditions which promote differentiation ( Fig 4C) . Flow cytometry analysis demonstrated that the NSPC marker, nestin, was still expressed in 70% of Pik3ca H1047R ;Pten  differentiated cells compared with 52% of control cells after seven days ( Fig. 4D ). Returning differentiated cells to serum-free neurosphere conditions, revealed a significantly higher sphereforming capacity in mutant cells (1 NSFU / 15.4 cells seeded), compared to control cells (1 NSFU / 36.0 cells seeded) ( Fig 4E) . Independent assessment by measuring nestin+, GFAP+ and Tuj-1+ cells grown on laminin for five days, supported the flow cytometric analysis with respect to an enhanced nestin+ cell stability under differentiating conditions. Mutant cells also exhibited higher GFAP+ cell numbers at day one but similar a number by day five, compared to parental wild-type NSPCs (Supplemental Fig. S5 ).
Analysis of a panel of PI3K/AKT pathway-associated phosphoproteins in NSPCs grown in vitro,
showed an upregulation of activation of numerous factors compared to parental control cells, including the factors: Akt, ribosomal protein S6 (rpS6), mTOR, GSK3, GSK3, p70S6 kinase, RSK1 and ERK1/2 (Fig. 5A ). To further investigate the possible biological basis of the enhanced neurosphere forming capacity observed in Pik3ca H1047R -Pten  NSPCs, we postulated that Wnt signaling was upregulated in mutant cells, as cross-talk between PI3K and Wnt signaling is common in stem cells 23 . Analysis of NSPCs showed that -catenin was expressed at higher levels in mutant cell nuclei, compared to wild-type cells (Fig. 5B ), indicating activation of Wnt signaling. Moreover, qRT-PCR demonstrated that the mRNA of Wnt pathway stem cell factors and targets was overexpressed in mutant NSPCs, compared to wild-type controls ( Fig 5C) .
Further analysis demonstrated that neurosphere forming potential could be modulated by chemical inhibitors which modulate the Wnt pathway (Fig. 5E ). CHIR99021 ('CHIR'), a potent GSK3 inhibitor, and Wnt pathway activator, increased neurosphere forming potential of mutant NSPCs, where sphere per cells seeded capacity ratio, was 1:1 for CHIR-treated NSPCs, compared to 1:2.6 for vehicle (DMSO) treated cells. Upstream inhibition of the Wnt pathway, using IWP-2, which targets the membrane-bound protein, porcupine, and inhibits Wnt protein secretion, did not have a significant effect on sphere forming capacity, compared to vehicle treated mutant NSPCs, suggesting that the PI3K modulates Wnt signals downstream from porcupine and receptor activation.
Creb1 deletion suppresses malignancy of Pik3ca H1047R -Pten  tumors
Most cells in Pik3ca H1047R -Pten  tumors expressed pCREB ( Fig. 2F ) and this expression overlapped with nestin and GFAP expressing SVZ cells (Fig. 6A ). We previously showed that mouse SVZ cells express activated pCREB 15 and human glioma tissue express high levels of both total CREB and pCREB 12 . To determine the contribution of CREB in brain tumor development and growth, we used CREB lox/lox mice 39 to generate triple mutant Pik3ca H1047R-lox -Pten lox/lox -CREB lox/lox -Nestin-CreER T2 mice, resulting in deletion of CREB in addition to the Pik3ca and Pten mutations in NSPCs (Pik3ca H1047R -Pten  -CREB  , hereafter referred to as 'triple mutant').
Triple mutant CREB  brain tumors exhibited the presence of large cells (Fig. 6B ) and circumscribed growth with little or no invasion into non-tumor brain parenchyma (Supplemental Fig. 6A ). We also observed a reduction in cell density in triple mutant CREB  tumors, compared to double mutant CREB wild-type tumors (Fig. 6B) , which was confirmed by counting cells in DAPI stained sections (Fig. 6C) , with triple mutant CREB  tumors exhibiting 65% cell density of Pik3ca H1047R -Pten  tumor cellularity. Notably, triple mutant CREB  mice were symptom-free for longer (median 125 days) following tamoxifen treatment, compared with double mutant Pik3ca H1047R -Pten  mice (median 70 days) ( Fig. 6D) .
To explore the proliferative potential of CREB  NSPCs, in vitro proliferation assays were performed and showed that triple mutant CREB  NSPC proliferation was reduced compared with Pik3ca H1047R -Pten  (Supplemental Fig. 6B ).
Consistent with the proliferation defect, cell cycle analysis showed that triple mutant CREB  NSPCs had fewer (5.9%) S-phase cells and more (80.2%) G0/G1 phase cells, compared to Pik3ca H1047R -Pten  (12.8% S-phase; 70% G0/G1-phase) NSPCs (Supplemental Fig. 6C ).
However, the sphere-forming capacity of CREB  NSPCs did not differ compared to Pik3ca H1047R -Pten  NSPCs (data not shown).
DISCUSSION
The role of the PI3K pathway in driving malignant astrocytic brain tumors comes from murine models in which activation of retroviral vector-encoded AKT needs to be coexpressed with a second potent oncogene, such as Ras or BRAF, to trigger tumor development and growth 22, 49 .
To our knowledge, no studies have demonstrated a direct involvement of PI3K subunit mutations. Recent large-scale cancer sequencing data suggest that PIK3CA may be a key driver of malignant astrocytic brain cancer 52 . Our study is the first to directly test the role of Pik3ca in brain tumor development and we demonstrate that expression of constitutive catalytically active Pik3ca H1047R can initiate tumor growth when targeted to NSPCs, although simultaneous deletion of tumor suppressor Pten was necessary for the development of invasive malignant tumors, similar to that reported in other murine brain cancer models, where a second driver gene/tumor suppressor loss is necessary to trigger development of malignant tumors 10, 26, 37 . In our model, homozygous loss of Pten only, did not lead to tumor development, although increased SVZ cellularity was observed, similar to the hyperproliferative neurogenic phenotype previously reported in Pten loxP/lox -Nestin-Cre mice 3, 20 .
The NSPC tumors in the mice presented with highly variable, heterogeneous histopathological features, a characteristic of high-grade astrocytic tumors/GBM in young adult patients 32 . The Pik3ca H1047R -Pten  tumors resemble some features commonly seen in patients with tuberous sclerosis, where mutations in the TSC1 and TSC2 genes, which encode factors downstream from the PI3K pathway, cause cortical layering defects, epilepsy, as well as the development of benign nodular subependymal tumors of the lateral ventricles 11 . However, a Tsc1 mutant mouse targeting NSPCS using a nestin-driven Tet-conditional transgene exhibits cortical disruption but no SVZ/ependymal tumors 18 . Moreover, the data we present demonstrate the inherent invasiveness of the Pik3ca H1047R -Pten  tumor cells, where prominent tumor cell migration/invasion into the white matter occurred, an important feature of malignant astrocytomas and GBM. Furthermore, coexpression of both the glial marker GFAP and neuronal marker TuJ1 revealed in our model is significant, since this coexpression pattern in patient astrocytic tumors is associated with aggressive astrocytic tumors 28 . Interestingly, tumors also exhibited rosette-like tumor cell arrangements tumors, which are features of both pediatric and young adult GBM 32 .
One of the major roadblocks toward effective treatment of patients with high grade malignant brain cancers is the invasiveness of tumor cells into healthy brain tissue, which renders tumor removal by surgery almost impossible. Our data also shows that Pik3ca H1047R -Pten  NSPCs exhibit enhanced migratory properties and sphere-forming/stem cell-associated characteristics, consistent with previous studies demonstrating that PI3K pathway activation promotes GBM cell migration 34 , neurosphere-formation and tumorigenicity of glioma stem cells (GSCs) 54 .
Using extreme limiting dilution analysis, we found that Pik3ca H1047R -Pten  NSPCs were able to efficiently maintain nestin expression and sphere-forming capacity, even after forced differentiation. This implies that the Pik3ca H1047R -Pten  mutations stabilize stem cell properties, and, in a clinical setting, these mutations may impart stable, therapy tumor cell resistant characteristics and the capacity for tumor recurrence/relapse. Phospho-protein analysis of PI3K/AKT downstream targets revealed an array of upregulated factors. Notably, GSK3a key factor in the PI3K/AKT pathway, exhibited increased phosphorylation in mutant NSPCs, compared with wild-type control cells. GSK3 is also integral for activation of the Wnt pathway 40 . Wnt and PI3K signaling are commonly co-activated in stem cells, which could explain the enhanced neurosphere forming capacity in Pik3ca H1047R -Pten  mutant NSPCs. Wnt signaling is a critical pathway for maintaining efficient self-renewal of NSPCs 27, 55 and is also implicated in maintenance of GSC self-renewal 47, 57 . The clinical importance of Wnt signaling in patient gliomas is highlighted by the correlation of Wnt factors with independent markers of poor prognosis 36 . Our data shows that Pik3ca H1047R -Pten  mutant NSPCs express high levels of all canonical Wnt pathway factors examined, except for the Wnt pathway receptor, Fzd7. Most of these genes examined have been reported to regulate NSPC and/or glioma cell biology. For example, the Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), plays a role in the maintenance and survival of patient-derived GSCs 42 ; Sox9 has a role in NSPC selfrenewal capacity 50 ; Myc inhibition disrupts mouse and human GSC self-renewal 4 . Notably, cooperation between the PI3K and WNT pathways plays a key role in hematopoietic stem cell self-renewal 46 , which may be similar to the cooperativity at play in NSPCs.
Cooperativity between the PI3K and MAPK pathways is suggested to be a requirement for GBM pathogenesis, explored in GBM in vitro and in vivo, using primary astrocytes with mutations in Kras and/or Pten 53 . The authors observed that each individual mutation caused upregulation of both the PI3K and MAPK pathway and that inhibition of one of the pathways inhibited tumorigenic potential.
Although the oncogenic roles and mechanisms involving cytoplasmic signaling pathways, such as the PI3K and MAPK pathways are still being deciphered, the transcriptional programs activated by oncogenic mutations are less well understood. We and others have shown that the kinase-inducible transcription factor CREB and its activated form, pCREB are expressed in human astrocytic tumors, including the most deadly form, GBM 5, 12 , and that CREB has a role in glioma cell proliferation 12 . Analysis of Pik3ca H1047R -Pten  tumor brain tissue and NSPC lysates, showed that aside from the expected upregulation of the PI3K/AKT pathway factors, the MAPK pathway was also upregulated. Our previous work shows that a transcriptional convergence point of the PI3K and MAPK pathways is CREB 12 . To explore the oncogenic role of CREB in vivo, we deleted CREB in Pik3ca H1047R -Pten  NSPCs. Strikingly, triple mutant Pik3ca H1047R -Pten  -CREB  mice were symptom-free for a longer period, compared with double mutant Pik3ca H1047R -Pten  mice. CREB deletion resulted in reduced tumor cellularity and a phenotypic shift of tumor cells toward a less malignant state, reminiscent of giant-cell GBM, which has a better prognosis compared with GBM 33 . Moreover, no invasion into white matter tracts was observed in triple mutant CREB  brains. To our knowledge, this is the first in vivo data demonstrating that genetically targeted loss of CREB in tumor cells suppresses tumor growth and is consistent with studies correlating elevated CREB expression and activation with poor prognosis in many neoplasms including those in lung 38 and breast 9 .
Overall, our data lead us to propose a model in which the PI3K pathway is critical and sufficient for reprograming normal NSPCs into tumor-initiating cells, in which the Wnt pathway is hyperactivated and contributes to NSPC self-renewal. As the resulting mutant tumor cells mature, the PI3K pathway activates a CREB-dependent transcriptome which contributes to tumor growth. MAPK signaling is also co-activated which probably contributes to CREB activation, to further fuel tumor cell proliferation. The putative efficacy of targeting CREB has led to the design of several experimental compounds which target CREB and can inhibit tumor cell proliferation in vitro and in vivo 56 . Indeed, co-targeting archetypal oncogenic pathways, including PI3K, MAPK and WNT, as well as transcription factors such as CREB, may prove to be effective therapeutic approaches for difficult to treat cancers, including HGGs, since transcription factors are less prone to direct mutations, thus circumventing the development of drug resistance 17 .
Materials and Methods
Ethics statement
Experiments in mice were carried out with the approval of The University of Melbourne, School of Biomedical Sciences (AEC No 1112336.1) and Peter MacCallum Cancer Center (AEEC No.
E406) Animal Ethics Committees.
Mouse maintenance and husbandry
Mice were housed at the Biomedical Sciences University of Melbourne animal house in a pathogen-free environment with food and water freely accessible. Environmental supplementation of the cages was limited to necessary bedding materials to standardize conditions between cages and mice. Pten lox/lox (c;129S4-Ptentm1Hwu/J) were from The Jackson Laboratory. Pik3ca H1047R-lox 29 , CREB lox/lox 39 , and Nestin-CreER T2 25 mice were generated, as previously described. All mice were on a C57BL/6 background.
In vivo tumor induction
Control (Pik3ca H1047R-lox -PTEN lox/lox ), double mutant (Pik3ca H1047R-lox -PTEN lox/lox -Nestin-CreER T2 ) or triple mutant (Pik3ca H1047R-lox -PTEN lox/lox -CREB lox/lox -Nestin-CreER T2 ) mice were treated with tamoxifen at 6-8 weeks of age, as described previously 7 .
NSPC isolation and culture
Adult (6-10 week) control (Pik3ca H1047R-lox -PTEN lox/lox ), double mutant (Pik3ca H1047R-lox -PTEN lox/lox -Nestin-CreER T2 ) or triple mutant (Pik3ca H1047R-lox -PTEN lox/lox -CREB lox/lox -Nestin-CreER T2 ) mice were culled immediately before harvesting. Brains were placed in ice cold PBS before dissection of the SVZs and NSPCs were isolated as previously described 15 . NSPCs were grown in Dulbecco's modified eagle medium (DMEM) (Invitrogen, USA) with the addition of 2% B27 supplement (Invitrogen), 20 ng/mL basic fibroblast growth factor (b-FGF, Sigma, USA), and 40 ng/mL epidermal growth factor (EGF, Sigma). NSPC maintenance and passaging was performed as previously described 15 .
In vitro controls
For experiments involving NSPCs, mutant NSPCs were generated by transient (24h) treatment with 0.02mg/ml 4-OH-T (in methanol) to induce Cre-mediated recombination of floxed alleles, while control cells were derived from the same genotype but treated with vehicle only (methanol). 4-OH-T was removed after 24h and never included in the medium in further experiments / assays.
Cell cycle analysis
Cells were dissociated and then resuspended in PBS. Cells were then fixed by adding cell solution dropwise into ice cold 100% ethanol. Fixed cells were kept at -20°C until day of analysis where they were washed 3x with PBS and then incubated with DAPI staining solution (5g/mL; Thermo Fisher Scientific, MA USA) for 15 minutes on ice. Following incubation, cells were washed, resuspended in PBS and immediately run on a LSR Fortessa using the UV laser (405nm). Cells were first gated with forward scatter width (FSW) vs DAPI (405nm) to exclude doublets and debris. A histogram of DAPI vs count was generated and analyzed on the flow cytometry analysis software FlowLogic (version 6) to identify the population (%) of cells in each of the cell cycle phases.
Proliferation assays
Cells were plated onto a 96 well plate and grown under required treatment conditions. On the day of analysis, Resazurin solution (Sigma, MO, USA) was diluted in appropriate media and added to wells to obtain a 10% v/v solution before incubation for at least 3 hours at 37°C. Plates were analyzed using the EnSpire Plate Reader (PerkinElmer).
Migration assay
Single neurospheres grown in DMEM-F12 with growth factors and supplements (see above) for 48h were placed into a 96-well plate (1 sphere/well) and assayed using the Trevigen 96-well 3D spheroid BME cell invasion assay kit (Bio Scientific, Australia), according to the manufacturer's protocol. Briefly, neurospheres were incubated either with (test) or without (control) addition of invasion matrix for 48h. Spheres were photographed on an inverted microscope and invasion area was calculated by measuring the area of invasion by subtracting the control neurosphere area using Image J (http://rsb.info.nih.gov/ij/index.html).
Extreme Limiting Dilution Analysis (ELDA)
Neurospheres were dissociated and plated in suspension media at decreasing cellular densities (20, 10, 5, 1 cell) using 24 wells per cell density condition. Wells were imaged 7 days after plating and the number of wells with one or more sphere, greater than ~20µm diameter, were scored. Data was analyzed as previously reported 24 using the online ELDA software hosted by WEHI (http://bioinf.wehi.edu.au/software/elda/). Cells were plated at 200,000 cells/9.61cm 2 in DMEM-F12 with 10%FCS and cultured for 7 days before subsequent analysis.
Flow cytometry analysis
Cells were harvested to single cell suspension as described above and resuspended in PBS. Cells were then fixed by adding cell solution dropwise into ice cold 100% ethanol. Fixed cells were kept at -20°C until day of analysis when they were washed 3x with PBS and then incubated for 
